1. Home
  2. UIS vs ALXO Comparison

UIS vs ALXO Comparison

Compare UIS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unisys Corporation New

UIS

Unisys Corporation New

HOLD

Current Price

$2.52

Market Cap

173.5M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.17

Market Cap

172.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UIS
ALXO
Founded
1942
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.5M
172.8M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
UIS
ALXO
Price
$2.52
$1.17
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
★ $4.81
$4.60
AVG Volume (30 Days)
682.8K
★ 1.4M
Earning Date
11-04-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.36
EPS
N/A
★ N/A
Revenue
★ $1,950,100,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.84
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.97
$0.86
52 Week High
$4.98
$2.66

Technical Indicators

Market Signals
Indicator
UIS
ALXO
Relative Strength Index (RSI) 61.45 42.79
Support Level $2.13 $0.86
Resistance Level $2.61 $1.29
Average True Range (ATR) 0.10 0.14
MACD 0.04 0.03
Stochastic Oscillator 98.75 69.20

Price Performance

Historical Comparison
UIS
ALXO

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: